Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(FY)Aug 31, 2024 | (Q4)Aug 31, 2024 | (Q3)May 31, 2024 | (Q2)Feb 29, 2024 | (Q1)Nov 30, 2023 | (FY)Aug 31, 2023 | (Q4)Aug 31, 2023 | (Q3)May 31, 2023 | (Q2)Feb 28, 2023 | (Q1)Nov 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 7.46%9.31B | 14.48%2.61B | 12.01%2.25B | 2.92%2.54B | 0.13%1.9B | -1.39%8.66B | -0.54%2.28B | -0.17%2.01B | -3.58%2.47B | -0.75%1.9B |
Cost of revenue | 8.77%3.45B | 18.23%990.12M | 13.48%855.1M | 1.77%911.19M | 1.18%694M | -0.93%3.17B | -2.57%837.42M | 3.99%753.51M | -5.42%895.37M | 2.22%685.9M |
Gross profit | 6.70%5.86B | 12.31%1.62B | 11.12%1.39B | 3.58%1.63B | -0.47%1.21B | -1.65%5.49B | 0.68%1.44B | -2.52%1.25B | -2.50%1.58B | -2.34%1.22B |
Operating expense | 5.49%5.59B | 10.02%1.47B | 4.85%1.33B | -0.81%1.39B | 8.30%1.39B | 2.36%5.29B | -0.58%1.34B | 5.23%1.27B | 0.03%1.41B | 5.45%1.28B |
Operating profit | 39.90%270.42M | 41.79%147.79M | 488.33%61.85M | 39.81%238.2M | -171.33%-177.42M | -52.56%193.29M | 20.24%104.23M | -120.05%-15.93M | -19.39%170.38M | -318.18%-65.39M |
Net non-operating interest income (expenses) | -7.20%-80.94M | -13.95%-19.15M | -18.04%-22.66M | -4.29%-20.41M | 6.08%-18.72M | -11.15%-75.5M | 10.41%-16.81M | 4.74%-19.2M | -2.33%-19.57M | -101.40%-19.94M |
Non-operating interest income | 49.43%3.42M | -41.85%949K | 122.71%804K | 560.00%1.19M | 315.65%478K | 42.20%2.29M | 193.00%1.63M | 46.15%361K | -71.06%180K | -37.16%115K |
Non-operating interest expense | 8.44%84.36M | 9.01%20.1M | 19.97%23.46M | 9.36%21.6M | -4.24%19.2M | 11.87%77.79M | -4.54%18.44M | -4.13%19.56M | 0.02%19.75M | 98.89%20.05M |
Net investment income | -14.55%50.05M | -140.87%-7.18M | -7.12%19.79M | 543.26%14.71M | 30.55%22.74M | -30.00%58.58M | -38.04%17.57M | -20.57%21.31M | -84.51%2.29M | 26.76%17.42M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | 50.98%-11.9M | 44.31%-11.59M | 32.39%-24.27M | 10.92%-20.81M | ||||||
Less:Other special charges | 27.58%4.47M | 9,151.11%4.16M | ---- | ---- | ---- | -72.04%3.51M | --45K | ---- | ---- | ---- |
Less:Write off | -64.24%7.42M | ---- | ---- | ---- | ---- | -11.11%20.76M | ---- | ---- | ---- | ---- |
Other non-operating income (expenses) | 19.52%-13.22M | -13.04%-3.14M | -4.25%-2.87M | -24.20%-4.14M | 59.38%-3.07M | -228.99%-16.42M | -54.62%-2.78M | -131.42%-2.75M | -435.45%-3.33M | -258.45%-7.56M |
Income before tax | 58.04%214.42M | 31.12%106.73M | 378.66%55.8M | 52.48%228.36M | -133.84%-176.48M | -66.09%135.67M | 14.44%81.4M | -122.41%-20.03M | -26.94%149.77M | -318.49%-75.47M |
Income tax | -3.20%75.37M | -34.69%35.88M | 921.81%22.42M | 2.57%35.65M | -103.93%-18.59M | -44.77%77.86M | 66.00%54.94M | -109.78%-2.73M | -34.55%34.76M | -133.94%-9.11M |
Net income | 140.52%139.05M | 167.75%70.85M | 293.00%33.39M | 67.56%192.71M | -137.95%-157.89M | -77.69%57.81M | -30.42%26.46M | -128.14%-17.3M | -24.29%115.01M | -963.56%-66.36M |
Net income continuous operations | 140.52%139.05M | 167.77%70.85M | 293.00%33.39M | 67.56%192.71M | -137.95%-157.89M | -77.69%57.81M | -30.42%26.46M | -128.14%-17.3M | -24.29%115.01M | -963.45%-66.36M |
Noncontrolling interests | ||||||||||
Net income attributable to the company | 140.52%139.05M | 167.75%70.85M | 293.00%33.39M | 67.56%192.71M | -137.95%-157.89M | -77.69%57.81M | -30.42%26.46M | -128.14%-17.3M | -24.29%115.01M | -963.56%-66.36M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 140.52%139.05M | 167.75%70.85M | 293.00%33.39M | 67.56%192.71M | -137.95%-157.89M | -77.69%57.81M | -30.42%26.46M | -128.14%-17.3M | -24.29%115.01M | -963.56%-66.36M |
Gross dividend payment | ||||||||||
Basic earnings per share | 139.58%117.42 | 166.73%59.8 | 291.44%28.18 | 66.68%163.01 | -136.45%-133.57 | -77.83%49.01 | -30.65%22.42 | -128.14%-14.72 | -24.68%97.8 | -959.82%-56.49 |
Diluted earnings per share | 140.18%112.07 | 167.29%57.04 | 282.81%26.91 | 66.94%162.581 | -136.45%-133.57 | -77.75%46.66 | -30.08%21.34 | -129.55%-14.72 | -20.91%97.3879 | -1,003.84%-56.49 |
Dividend per share | 0.00%20 | 0.00%20 | 0 | 0 | 0 | 0.00%20 | 0.00%20 | 0 | 0 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |